USPTO serial 77602824
B BEAUFORT
Reviewed by CopyMark Law Group
Reg. 3825880Status 710
- Filing date
- Status date
- Registration date
- Jul 27, 2010
- Examiner
- GAYNOR, BARBARA ANNE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with B BEAUFORT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Timothy J. Lockhart
TIMOTHY J. LOCKHART WILLCOX & SAVAGE P.C.1 COMMERCIAL PL #1800ATTN: IP ADMINISTRATORNORFOLK, VA 23510-2115Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Regulatory submission management, namely, assisting others in preparing Investigational New Drug applications (INDs) and New Drug Applications (NDAs) for submission to the FDA; database management | SECTION 8 - CANCELLED | Jun 25, 2009 |
| 040 | Consulting services in the field of manufacturing compliance and validation, namely, providing technical advice related to the manufacture of pharmaceuticals | SECTION 8 - CANCELLED | Jun 25, 2009 |
| 042 | Contract research organization (CRO) services, namely, monitoring of clinical trials for investigational drugs of biotech and pharmaceutical companies, clinical trial project management and quality assurance, medical writing of investigational drug protocols, and medical research in the nature of biostatistical analysis; consulting services in the field of conducting clinical trials, drug development, manufacturing environmental compliance and validation, advanced technology in the pharmaceutical field, and medical research in the nature of clinical benchmarking used to improve the performance of professionals in the fields of international health, the pharmaceutical industry, the biotechnology industry and the medical device and diagnostics industries; providing quality assurance services in the field of regulatory submissions to the FDA by life sciences companies to ensure validity and accuracy; product development for others, namely, providing implementation services relating to the development and validation of drugs, devices and biologics | SECTION 8 - CANCELLED | Jun 25, 2009 |
| 045 | Legal research, namely, regulatory research in the pharmaceutical industry, biotechnology industry and the medical and diagnostics industry; consultation in the field of regulatory compliance to ensure validity and accuracy of regulatory submissions to the FDA by life sciences companies; conducting regulatory and compliance audits for others, namely, reviewing standards and practices to assure compliance with laws and regulations in the fields of pharmaceutical, veterinary, pharmacogenomic, biotechnical and medical products and devices; providing information relating to legal affairs, namely, providing regulatory information relating to the development and validation of drugs, devices and biologics; regulatory compliance consulting as it applies to clinical trials, namely, monitoring by clinical research administrators for compliance with regulations governing clinical trials; legal document preparation services, namely, preparation of Investigational New Drug applications (INDs) and New Drug Applications (NDAs) for submission to the FDA; consulting services in the field of regulatory affairs and manufacturing compliance and validation, namely, regulatory compliance consulting as it applies to prescription drug sampling; consulting services in the field of clinical benchmarking and performance improvement, namely, providing independent review of clinical trials involving human subjects in the nature of reviewing research protocols and related information to ensure protection of the rights and welfare of human subjects of research | SECTION 8 - CANCELLED | Jun 25, 2009 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BEAUFORT, LLC
- Other trademarks owned by Beaufort Advisors, LLC
- Other trademarks owned by Beaufort Advisors, LLC
- Other trademarks owned by BEAUFORT, LLC
- Other trademarks in Class 035
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 045
- Similar marks named B BEAUFORT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 3, 2017 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jun 20, 2016 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jun 20, 2016 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jul 27, 2010 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 19, 2010 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Jun 18, 2010 | REGV | LAW OFFICE REGISTRATION REVIEW COMPLETED | — |
| Jun 18, 2010 | ALIE | ASSIGNED TO LIE | — |
| Jun 3, 2010 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| May 19, 2010 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 26, 2010 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Apr 26, 2010 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Apr 8, 2010 | IUAF | USE AMENDMENT FILED | — |
| Apr 8, 2010 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Apr 7, 2010 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Apr 6, 2010 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 2, 2010 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Apr 2, 2010 | EXT1 | SOU EXTENSION 1 FILED | — |
| Apr 2, 2010 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 6, 2009 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 14, 2009 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 24, 2009 | NPUB | NOTICE OF PUBLICATION | — |
| Jun 8, 2009 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jun 8, 2009 | ALIE | ASSIGNED TO LIE | — |
| Jun 5, 2009 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 2, 2009 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 2, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 2, 2009 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 3, 2009 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 3, 2009 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 3, 2009 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 27, 2009 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 4, 2008 | MDSC | NOTICE OF DESIGN SEARCH CODE MAILED | — |
| Nov 3, 2008 | NWAP | NEW APPLICATION ENTERED | — |